Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MiRNA expression data from pancreatic ductal adenocarcinoma (PDAC) cell line BxPC3 and its cisplatin-resistant derivative BxPC3-R

ABSTRACT: Differential expression of miRNAs between parental and cisplatin-resistant PDAC cells was analyzed to elucidate the role of miRNAs in the acquired resistance of pancreatic cancer cells to cisplatin. Cisplatin-resistant BxPC3-R cells were developed from the parental BxPC3 cell line by culturing them in medium with step-wise increasing concentration of cisplatin.

ORGANISM(S): synthetic construct Homo sapiens

PROVIDER: GSE79506 | GEO | 2016/05/01

SECONDARY ACCESSION(S): PRJNA316006

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression data from pancreatic ductal adenocarcinoma (PDAC) cell lines AsPC1, BxPC3 and their cisplatin-resistant derivatives AsPC1-R and BxPC3-R

Project description:Cisplatin is a broad-spectrum anticancer drug, which is estimated to be administered to 40-80% of patients undergoing chemotherapy. However, its clinical utility is often limited due to factors that include acquired resistance of cancer cells to cisplatin. Because cisplatin is currently evaluated as a prospective agent for combined chemotherapy of pancreatic ductal adenocarcinoma (PDAC), we have investigated mechanisms involved in the acquired resistance of PDAC cells to cisplatin using gene expression study of two different parental-resistant pairs of PDAC cell lines. We have developed cisplatin-resistant cell lines AsPC1-R and BxPC3-R from their parental PDAC cell lines AsPC1 and BxPC3, respectively, by culturing them in medium with step-wise increasing concentration of cisplatin. Parental and resistant pairs of PDAC cells were analyzed by whole-transcript gene expression analysis.

2015-11-30 | GSE73978 | GEO

DDR1 knockdown in BXPC3 cell line

Project description:Examination of effect of stable DDR1 knockdown by shRNA on transcriptional profile in BXPC3 cell line to understand role of DDR1 in tumorigenesis. Transcriptional profiles of parental BXPC3 cell line was compared to BXPC3 cells stably transfected with non-target shRNA or DDR1 shRNA, N=3 for each condition.

2014-05-01 | E-GEOD-39207 | biostudies-arrayexpress

Gene Expression in Cisplatin Resistance HeLa Cells

Project description:Cisplatin resistance is a problem in cancer treatment. Using DNA microarray, we detected differentially expressed genes in cisplatin-resistant cervix carcinoma HeLa cells compared to parental cells. Three cisplatin resistant cell lines were established by stepwise increasing cisplatin concentration. RNA from these resistant lines and its parental HeLa cells were labeled with Cy5 and Cy3. Equal amount of RNA from resistant cell line and HeLa were mixed and were hybridized to cDNA array. Signals were scanned and analyzed to find out the candidate genes involved in cisplatin resistant mechanism.

2010-05-06 | E-GEOD-15120 | biostudies-arrayexpress

mRNA-seq of gemcitabine resistant pancreatic cancer cell line subclones derived from BxPC3

Project description:We generated gemcitabine resistant subclones from the human pancreatic cancer cell line BxPC3 using chronic low dose exposure to gemcitabine. Three gemcitabine resistant subclones (BxGR-80C, BxGR-120C and BxGR-360C) were sequenced in addition to BxPC3 cells.

2021-12-21 | E-MTAB-11186 | biostudies-arrayexpress

MiRNA Expression Profiling in Cisplatin Resistance Human Gastric Cancer Cell Lines and Their Parental Cell Lines

Project description:Cisplatin is the first-line agent utilized for the clinical treatment of a wide variety of solid tumors including gastric cancer. However, the intrinsic or acquired cisplatin resistance is often occurred in patients with gastric cancer and resulted in failure of cisplatin therapy. In order to investigate if miRNA involves in cisplatin resistance of human gastric cancer, we first screened and compared the expression of miRNAs between cisplatin resistant gastric cancer cell lines SGC-7901/DDP and BGC-823/DDP and their sensitive parental cells by miRNAs microarray.

2016-09-05 | GSE86195 | GEO

Analysis of miRNA sublocalization in cisplatin-resistant versus parental CAL-27 cells

Project description:Chemoresistance frequently leads to therapeutic failure in oral squamous cell carcinoma (OSCC). While miRNA have been widely reported having global regulatory roles in cancer biological properties, yet their localiztion alteration under cisplatin treatment has not been clarified. In this study, to identify the sublocalization characteristics of miRNAs induced by chemotherapy, especially the specific mitochondrial localization of miRNA, we profile the expression of miRNAs in cisplatin-resistant and parental TSCC cells using miRNA microarrays.

2018-06-12 | GSE115118 | GEO

Gene Expression in Cisplatin Resistance HeLa Cells

2010-03-05 | GSE15120 | GEO

Gene expression profile in cisplatin-resistant lung cancer cells

Project description:Gene expression profile in parental and cisplatin-resistant A549 cells

2020-09-29 | GSE158638 | GEO

Characterization of Germ Cancer Cell lines resistant to Cisplatin

Project description:Comparing parental and derived cisplatin resistant cell lines.

2022-06-01 | E-MTAB-9114 | biostudies-arrayexpress

Next generation sequencing analysis of mRNA profile in cisplatin-resistant gastric cancer cell line SGC7901

Project description:Cisplatin-resistant gastric cancer (GC) occurs in patients with GC treated with cisplatin-based chemotherapy, which results in disease progression and early recurrence during the treatment. To understand the initiation and developmental mechanism underlying cisplatin-resistant GC, we developed cisplatin resistant SGC7901 cells (SGC7901/DDP) from the parental cells (SGC7901/S) by continuous exposure to increasing concentrations of cisplatin and subjected these two cell lines to RNA sequencing analysis.

2019-04-17 | GSE122130 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data